There are exceptions, of course; however, all told, cancer-drug candidates are a sucker bet, IMHO.
Too often, I feel that way about most, if not all, biotech stocks. The real winners have beem few and far between. For every AMGN, BIIB, GILD, etc., there have been probably twenty that have come and gone. Bty it sure has been fun to follow.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.